AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00423436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response Telephone System
Description: IVR Only = Phone calls twice weekly, each call lasting less than 5 minutes.
Study NCT00423436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IVR Plus Triage
Description: IVR system will triage, or sort, the symptom data by symptom severity, notifying health care professionals when a symptom is greater than the set threshold limit.
Study NCT00639639 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Given IV
Study NCT04533334 — intervention group
Intervention type: PROCEDURE
Intervention: FOB measurement
Description: A FOB will be inserted after anesthesia induction and the distances will be measured by direct observation via the bronchoscope.
Study NCT03391778 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADP adoptive cell therapy
Description: No study drug is administered in this study. Participants who received ADP adoptive cell therapy in a previous trial will be evaluated in this trial for long-term safety and efficacy.
Study NCT00787345 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: simulation based training
Description: simulation based training in aseptic techniques that included specified AT categories
Study NCT01256398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV
Study NCT01256398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Phosphate
Description: Given IV
Study NCT02912533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR-131
Study NCT02032901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Study NCT02032901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Study NCT02419157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selective enamel etching with 36% phosphoric acid
Description: Etch: selective 36% phosphoric acid enamel etching
Study NCT02419157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No selective enamel etching with 36% phosphoric acid
Description: Non-etch: without phosphoric acid selective enamel etching
Study NCT02419157 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clearfil SE Bond
Study NCT02419157 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xeno V
Study NCT01722331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tildrakizumab 200 mg
Description: Two tildrakizumab 100 mg/mL pre-filled syringes (PFS)
Study NCT01722331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg
Description: Two tildrakizumab 100 mg/mL pre-filled syringes (PFS)
Study NCT01722331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tildrakizumab 100 mg
Description: Tildrakizumab 100 mg/mL PFS
Study NCT01722331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg
Description: Tildrakizumab 100 mg/mL PFS
Study NCT01722331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching placebo to tildrakizumab PFS
Study NCT01722331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Matching placebo to tildrakizumab PFS
Study NCT01621360 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic hip surgery
Description: Hip arthroscopy
Study NCT01621360 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Physical therapy aimed at strengthening and stabilization of the hip and appropriate analgesic and anti-inflammatory medication.
Study NCT03556761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral furosemide
Description: Furosemide (Lasix), 20 milligram, PO, PO, daily
Study NCT03556761 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo, PO, daily
Study NCT03876041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solumedrol
Description: intravenous solution for injection
Study NCT03759262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: A single dose of ultra-high-dose vitamin D (cholecalciferol) will be given prior to hematopoietic stem cell transplant. Research labs including inflammatory biomarker panels will be obtained prior to and after the dose is given.
Study NCT01256398 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study NCT01256398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT01256398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In Vitro-Treated Peripheral Blood Stem Cell Transplantation
Description: Undergo peripheral blood autologous or allogeneic HCT
Study NCT01256398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01256398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV or PO
Study NCT01256398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT01256398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO
Study NCT01256398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, IV, or PO
Study NCT01256398 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC
Study NCT01256398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01256398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study NCT01256398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT01304953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group P+P
Description: In this arm, anaesthesia was maintained with propofol and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely propofol was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received saline placebo i.v. after the induction of anaesthesia.
Study NCT01304953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group P+T
Description: In this arm, anaesthesia was maintained with propofol and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely propofol was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received tropisetron 2 mg i.v. after the induction of anaesthesia.
Study NCT03876041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone phosphate
Description: intravenous solution for injection
Study NCT00721526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: disulfiram plus lorazepam
Description: Disulfiram 500mg three times weekly lorazepam 0.5-2.0 mg three times daily
Study NCT02894645 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine
Description: Intravenous
Study NCT01493609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Click-East app
Description: Computer game, delivered as an iPad app, designed to provide an environment to practice basic social skills.
Study NCT02282449 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Power Injectable Port (AngioDynamics Smart Port CT Mini)
Description: The subjects will all receive power injectable port.
Study NCT02282449 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Power Injectable Port (Cook Vital Mini Port)
Description: The subjects will all receive non-power injectable port.
Study NCT03390452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Phone Messaging
Description: Parents of primary school children will receive Mobile Phone Messages regarding their children's oral hygiene maintenance and their positive dietary habits.
Study NCT02703454 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FIRM-guided RF ablation
Study NCT04007952 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior Gastropexy
Description: Two permanent sutures will be introduced into the abdomen and placed along the lesser curvature of the stomach. A suture passer will be used to grasp the ends of the sutures to externalize them at separate fascial punctures. At time of abdominal desufflation, the sutures will be tied and the incision closed per individual surgeon practice.
Study NCT03524391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselling based on yoga
Description: Counseling sessions were given as one-on-one and group to patients based on yoga philosophy and therapy.
Study NCT03524391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Usual Care group had standard chemotherapy regimens
Study NCT03524391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Usual Care group had standard chemotherapy regimens
Study NCT02403310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Induction: Oral selinexor on days 1, 3, 8, 10, 15 and 17.~* Dose Level 2: 80 mg twice weekly.~* Dose Level 1 (starting dose): 60 mg twice weekly.~* Dose Level -1: 40 mg twice weekly.~Consolidation: Selinexor same dose as induction (days 1,3,8,10) unless dose limiting toxicity (DLT) dictates a dose reduction.~Maintenance: Selinexor at the same dose as induction on days 1 and 8 a 21 day cycle. They will continue for a maximum of 12 months.
Study NCT02403310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Induction: Daunorubicin 60 mg/m\^2/day (days 1-3).~Consolidation: Daunorubicin 45 mg/m\^2/day (days 1-2).
Study NCT02403310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction: Cytarabine 100 mg/m\^2/day (days 1-7).~Consolidation: Cytarabine 100 mg/m\^2/day (continuous infusion on days 1-5).
Study NCT01304953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group S+P
Description: In this arm, anesthesia was maintained by sevoflurane and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely sevoflurane was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received saline placebo i.v. after the induction of anaesthesia.
Study NCT01304953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group S+T
Description: In this arm, anesthesia was maintained by sevoflurane and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely sevoflurane was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received tropisetron 2 mg i.v. after the induction of anaesthesia.
Study NCT01224509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Administration of 200 mg of mifepristone orally 48 hours prior to a cervical biopsy and evacuation by dilatation and curettage of the endometrial cavity
Study NCT01224509 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-treatment
Description: Non-treatment prior to a cervical biopsy and evacuation by dilatation and curettage of the endometrial cavity
Study NCT03856424 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Modality 1
Description: Pressure support ventilation (PSV) modality
Study NCT02703454 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional RF ablation
Study NCT00414986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard CQI intervention
Description: In-practice change facilitator assists the practice in implementing a chronic disease registry
Study NCT00414986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Care Improvement (CCI) Intervention
Description: An in-practice change facilitator will assist the Improvement Team in enhancing the relationship infrastructure of the practice and in implementing diabetes and depression office systems.
Study NCT00414986 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-directed practice comparison
Description: Practices will have access to all tools used in Arm 1 via a project website
Study NCT02060240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Activity
Description: The high activity group will undergo a 12 week ramped exercise protocol.
Study NCT00282425 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Description: Allogeneic Hematopoietic stem cell transplantation
Study NCT04415177 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EaseVRx headset with active intervention
Description: VR software developed by AppliedVR informed by evidence-based cognitive behavioral therapy principles, biofeedback and mindfulness strategies for pain management.
Study NCT04415177 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EaseVRx headset without active intervention
Description: VR software developed by AppliedVR with neutral non-interactive content.
Study NCT03006822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure release 90
Description: This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
Study NCT03006822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure release 60
Description: This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
Study NCT03006822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure release 30
Description: This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
Study NCT03878940 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Abdominal ´yes-no´ pathway
Description: A set of blood samples, a FIT, and an abdominal US (and a TVUS in women)
Study NCT03750136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Description: high dose furosemide with hypertonic saline 3x daily
Study NCT03750136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide Injection
Description: high dose furosemide
Study NCT03750136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Injection
Description: high dose furosemide
Study NCT01542775 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise Group
Description: 12 weeks Aerobic exercise
Study NCT01542775 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: maintaining usual activities
Study NCT02109055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: The exercise program will be held during the period of hospitalization for six days, often two to three sessions per day, totaling 12 sessions.
Study NCT02109055 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy
Description: The conventional physiotherapy group will continue with the routine hospital consisting of respiratory physiotherapy, twice daily, six days.
Study NCT03354000 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Take-home online training
Description: We randomized patients to receive a link to access the online tutorial on their own. Participants in the take-home arm were given a paper handout with a link to the training materials and an outline of the steps for accessing the training curriculum.
Study NCT03354000 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person online training
Description: For participants randomized to the in-person training arm, a trained research assistant prompted participants to log into the learning platform and guided them in accessing the training materials for portal features that were of interest to them. The staff member provided further explanation or clarification if participants had questions about the training material.
Study NCT02504645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPP-201101
Study NCT02504645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02504645 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Study NCT02504645 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Study NCT01854554 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMPT
Description: IMPT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
Study NCT01854554 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: IMRT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
Study NCT01854554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Tests
Description: Cognitive tests given at baseline, 4 months, then every 2 months for 2 years.
Study NCT03756207 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: multidisciplinary bladder-preservation therapy
Description: Maximal transurethral resection followed by radiotherapy with concomitant radio-sensitizing chemotherapy
Study NCT00424515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib was given at a dose of 400 mg orally daily (4 100mg pills). Patients received treatment up to 12 months as long as they were receiving clinical benefit. Dosage may have been increased to twice daily if disease worsened and patient was in otherwise good clinical condition.
Study NCT00826176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was to be administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium intravenous (IV) could have been administered if necessary. At 1-2 PTC after the last administration of rocuronium, an IV single bolus dose of 4.0 mg/kg sugammadex was to be administered.
Study NCT00351078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC124
Description: 4-,4-, and 8-mg/kg PO first 14 days 10-, 10-, and 20-mg/kg TID second 14 days
Study NCT00795483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic Acid 5mg/year
Study NCT00795483 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modifications
Description: Lifestyle modifications
Study NCT00795483 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle modifications
Description: Lifestyle modifications
Study NCT00795483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic acid (5mg/2years)
Study NCT01336218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: oral tablets, 150mg (3 X 50mg) single dose per period
Study NCT01336218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampicin
Description: oral tablets, 600mg (2 X 300mg) 8 doses over 8 days
Study NCT00732784 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Imatinib mesylate
Description: Dosage form: tablets Dosage: 400 mg Frequency \& duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
Study NCT00732784 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: calcium carbonate
Description: Dosage form: tablets Dosage: 4000 mg (4 x 1000 mg tablet) Frequency: On an 18-day schedule, once daily day 15 (for Arm 1); or once daily day 1 (for Arm 2)
Study NCT01933412 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sci-B-Vac Hepatitis B Vaccine
Description: Sci-B-Vac Hepatitis B Vaccine
Study NCT01933412 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix B Hepatitis B Vaccine
Study NCT03795064 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Foam sclerotherapy
Description: Foam sclerotherapy is used to all patients for endovenous ablation of insufficient veins in subulcer plexus area.
Study NCT03795064 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Foam sclerotherapy
Description: Foam sclerotherapy is used to all patients for endovenous ablation of insufficient veins in subulcer plexus area.
Study NCT03795064 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endothermal ablation
Description: Endothermal ablation is performed in early setting when truncal vein(s) anatomy is suitable.